AGC Biologics vs KBI Biopharma: CDMO Comparison

How does AGC Biologics compare to KBI Biopharma?

As of Oct 2026, AGC Biologics: 4 FDA inspections (including 1 NAI, 3 VAI and 0 OAI), 27 EMA/MHRA GMP certificates. Signal Score 79.9. KBI Biopharma: 2 FDA inspections (including 0 NAI, 2 VAI and 0 OAI), 1 EMA/MHRA GMP certificate. Signal Score 84.1. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of AGC Biologics and KBI Biopharma on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score
80/100
Quality (FDA + GMP)
100/100
FDA inspections
4
— NAI / VAI / OAI
1 / 3 / 0
FDA warning letters
0
EMA GMP certificates (active)
27
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
2
Capacity
Available
Modalities
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Durham, NC · Boulder, CO
Signal Score
84/100
Quality (FDA + GMP)
98/100
FDA inspections
2
— NAI / VAI / OAI
0 / 2 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
Limited
Modalities
Monoclonal Antibody, Recombinant Protein, AAV (analytical only), Plasmid DNA

Key differences

  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • AGC Biologics holds 27 active EMA GMP certificates; KBI Biopharma does not appear in EudraGMDP.
  • KBI Biopharma maintains 1 MHRA / UK GMP certificate; AGC Biologics does not.

Across the cross-modality scorecard, KBI Biopharma carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: AGC Biologics vs KBI Biopharma

How does AGC Biologics compare to KBI Biopharma?

On CDMO Signal's composite Signal Score, AGC Biologics is 80/100 and KBI Biopharma is 84/100; AGC Biologics has 4 FDA inspections on record vs 2 for KBI Biopharma; European coverage is 27 active EMA+MHRA certificates for AGC Biologics vs 1 for KBI Biopharma. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, AGC Biologics or KBI Biopharma?

Both AGC Biologics and KBI Biopharma maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. AGC Biologics has 4 FDA inspections on record; KBI Biopharma has 2.

How do AGC Biologics and KBI Biopharma compare on European GMP coverage?

AGC Biologics holds 27 active EMA GMP certificates and 0 MHRA / UK certificates. KBI Biopharma holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — AGC Biologics or KBI Biopharma?

AGC Biologics is matched to 2 ClinicalTrials.gov records as a manufacturing partner; KBI Biopharma is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

What does the Signal Score gap mean in practice?

AGC Biologics carries a Signal Score of 80/100 and KBI Biopharma carries 84/100 — essentially tied for KBI Biopharma. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating AGC Biologics and KBI Biopharma for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.